Longevity & AgingNew Oral NLRP3 Inhibitor Cuts Inflammation 86% in Early Heart Disease Trial
BioAge Labs has launched a mid-stage clinical trial testing BGE-102, an oral pill designed to reduce chronic inflammation linked to heart disease. The drug works by blocking NLRP3, a key driver of harmful inflammation in the body. In earlier Phase 1 testing, BGE-102 cut levels of hsCRP — a major blood marker of cardiovascular risk — by a median of 86% at select doses. The new Phase 2 trial, called QUELL-CV, will enroll around 160 adults at elevated cardiovascular risk over 12 weeks, testing three different daily doses against placebo. Results are expected in late 2026. If confirmed, a drug that dramatically lowers inflammatory biomarkers with a once-daily pill could become a meaningful new tool for reducing heart disease risk.
